Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb and 360Dx.
The tool combines geographical data on viral mutations with an easy-to-use interface to check whether primers may be affected.
The Hopkins team expects to spinout a company soon in order to commercialize the technology in the next two to three years.
The firm expects to soon carve out a share in the rapidly expanding point-of-care, infectious disease, molecular diagnostics market.
Miniaturized sample-to-answer devices in development hint at an evolving molecular diagnostics landscape but launch timelines for these platforms remain unclear.
Four newly published PCR variant assays could potentially help health officials surveil communities and triage patients.
The firm expects an expanding market for at-home self-testing and is differentiating its products in part through their ease of use.
On a call with investors this week, the firm described massive revenue increases and discussed how it plans to sustain and deploy these gains.
The firm's over-the-counter claim submission is delayed because it has been unable to find the required number of positive cases among asymptomatic people.
With $1.2 billion in funding earmarked for more than 40 projects, the portfolio represents a path out of the SARS-CoV-2 pandemic for the US.
Executives mapped out the next few years for the firm, estimating a deceleration in COVID-19 testing beginning the second half of 2021.